A Clinical Guide to Combination Lipid-Lowering Therapy
Purpose of Review
We provide an overview of our current understanding of combination lipid-lowering therapies intended for dyslipidemia treatment and cardiovascular disease prevention. First, we analyze recent statin and non-statin combination therapy guidelines and clinical studies since the publication of 2013 American College of Cardiology Cholesterol Guidelines. Second, we examine the clinical utility of non-statin agents alone and in combination in terms of LDL-C lowering and ASCVD risk reduction.
Medical societies, including the American College of Cardiology (ACC), National Lipid Association (NLA), and American Association of Clinical Endocrinologists (AACE), have released guidelines to address the appropriate use of non-statin therapies. The guidelines incorporated new evidence, including the IMPROVE-IT and FOURIER clinical trials, which demonstrate that the combination of statin therapy with other non-statin agents such as ezetimibe and PCSK9 inhibitors has a significant clinical benefit. Increasing evidence that aggressive low-density lipoprotein cholesterol (LDL-C) lowering leads to lower cardiovascular disease risk supports the need for continued exploration of the role of combination lipid-lowering therapies.
A review of guidelines and clinical trials evaluating non-statin agents illuminates the growing base of evidence and expert opinion supporting the use of combination lipid-lowering therapies. While the majority of clinical trial data utilizes dyslipidemia monotherapy, especially statins, combination therapies represent an opportunity for individualized, patient-centered approach to LDL-C lowering and atherosclerotic cardiovascular disease (ASCVD) risk reduction. The overview provides a perspective on lipid management intended for clinicians who seek additional information and guidance on the use of combination therapies.
KeywordsClinical practice guidelines Atherosclerotic cardiovascular disease (ASCVD) Dyslipidemia PCSK9 inhibitors Non-statins Cardiovascular disease prevention Ezetimibe Low-density lipoprotein cholesterol (LDL-C) LDL-C targets
Compliance with Ethical Standards
Conflict of Interest
Cori Russell, Samip Sheth, and Douglas Jacoby declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45.CrossRefPubMedGoogle Scholar
- 5.• Jacobson TA, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473–88. This document provides recommendations for the use of non-statin agents for reduction of LDL-C and ASCVD as well as introduces new LDL-C targets. CrossRefPubMedGoogle Scholar
- 9.•• Writing C, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92–125. This document provides a clinical algorithm for the use of non-statin agents in combination with statins for further LDL-C and ASCVD risk reduction. CrossRefGoogle Scholar
- 10.• Jellinger PS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87. These guidelines created a new category of ‘extreme risk’ for ASCVD and suggested a lower LDL-C goal of < 55 mg/dL. CrossRefPubMedGoogle Scholar
- 13.• Lloyd-Jones DM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(14):1785–822. This document provides an update to the 2016 ACC Expert Consensus Pathway taking into account the results of the FOURIER trial and provides further support for the use of PCSK9 inhibitors in combination therapy. CrossRefPubMedGoogle Scholar
- 16.Karalis, D.V., B; Ahedor, L; and Liu, L., Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol, 2012. 2012: p. Article ID 861924.Google Scholar
- 23.• Adhyaru BB, Jacobson TA. Role of non-statins, LDL-C thresholds, and special population considerations: a look at the updated 2016 ACC Consensus Committee Recommendations. Curr Atheroscler Rep. 2017;19(6):29. This article reviews the role of non-statin agents in combination with statins for LDL-C and ASCVD risk reduction after the publication of the 2016 ACC Expert Consensus Pathway and the 2015NLA Recommendations. CrossRefPubMedGoogle Scholar